Non-alcoholic Steatohepatitis Market, Global Outlook and Forecast 2024-2030

Report ID
46679
Publisher
Market Monitor Global
Published Date
07-Feb
Delivery Format
PDF
No of Report Page
110
Editor's Rating
US $3,250.00
US $4,225.00
US $4,875.00
  • Report Details
    This research report provides a comprehensive analysis of the Non-alcoholic Steatohepatitis market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Non-alcoholic Steatohepatitis market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Non-alcoholic Steatohepatitis, challenges faced by the industry, and potential opportunities for market players.
    The global Non-alcoholic Steatohepatitis market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Non-alcoholic Steatohepatitis market presents opportunities for various stakeholders, including Oral, Parenteral. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Non-alcoholic Steatohepatitis market. Additionally, the growing consumer demand present avenues for market expansion.
    The global Non-alcoholic Steatohepatitis market was valued at US$ 2388.1 million in 2023 and is projected to reach US$ 9466.4 million by 2030, at a CAGR of 21.7% during the forecast period.
    NASH is a progressive liver disease characterized by fat accumulation in the liver, inflammation, and liver cell damage, typically occurring in individuals who do not consume excessive alcohol. Several factors are driving the growth of the NASH market. Firstly, the rising prevalence of obesity and metabolic disorders, such as diabetes and dyslipidemia, is contributing to the increasing incidence of NASH. Unhealthy lifestyles, sedentary habits, and poor dietary choices are leading to a higher risk of developing NASH, creating a substantial patient population in need of diagnosis and treatment. Secondly, the improved understanding and awareness of NASH among healthcare professionals and the general population have resulted in increased diagnosis rates. As the medical community recognizes the long-term complications and progression of NASH, there is a greater emphasis on identifying patients with NASH and implementing appropriate management strategies.
    Key Features:
    The research report on the Non-alcoholic Steatohepatitis market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
    Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Non-alcoholic Steatohepatitis market.
    Market Overview: The report provides a comprehensive overview of the Non-alcoholic Steatohepatitis market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Solid, Liquid), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
    Market Dynamics: The report analyses the market dynamics driving the growth and development of the Non-alcoholic Steatohepatitis market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Non-alcoholic Steatohepatitis market's trajectory.
    Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Non-alcoholic Steatohepatitis market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments. 
    Market Segmentation and Forecast: The report segment the Non-alcoholic Steatohepatitis market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
    Technological Trends: The report should highlight the key technological trends shaping the Non-alcoholic Steatohepatitis market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
    Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Non-alcoholic Steatohepatitis market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
    Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Non-alcoholic Steatohepatitis, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
    Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Non-alcoholic Steatohepatitis market.
    Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
    Market Segmentation
    Non-alcoholic Steatohepatitis market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
    Market segment by Type
        Solid
        Liquid
    Market segment by Application
        Oral
        Parenteral
    Global Non-alcoholic Steatohepatitis Market Segment Percentages, By Region and Country, 2023 (%)
        North America
            US
            Canada
            Mexico
        Europe
            Germany
            France
            U.K.
            Italy
            Russia
            Nordic Countries
            Benelux
            Rest of Europe
        Asia
            China
            Japan
            South Korea
            Southeast Asia
            India
            Rest of Asia
        South America
            Brazil
            Argentina
            Rest of South America
        Middle East & Africa
            Turkey
            Israel
            Saudi Arabia
            UAE
            Rest of Middle East & Africa
    Major players covered
        AstraZeneca
        Pfizer
        GSK
        Novo Nordisk
        Roche
        AbbVie
        Galectin Therapeutics
        Galmed Pharmaceuticals
        Gilead
        Intercept pharma
        Non-alcoholic Steatohepatitis
        Takeda
    Outline of Major Chapters:
    Chapter 1: Introduces the definition of Non-alcoholic Steatohepatitis, market overview.
    Chapter 2: Global Non-alcoholic Steatohepatitis market size in revenue.
    Chapter 3: Detailed analysis of Non-alcoholic Steatohepatitis company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
    Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
    Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
    Chapter 6: Sales of Non-alcoholic Steatohepatitis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
    Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
    Chapter 8: The main points and conclusions of the report.
    
  • Table Of Content
    1 Introduction to Research & Analysis Reports
        1.1 Non-alcoholic Steatohepatitis Market Definition
        1.2 Market Segments
            1.2.1 Market by Type
            1.2.2 Market by Application
        1.3 Global Non-alcoholic Steatohepatitis Market Overview
        1.4 Features & Benefits of This Report
        1.5 Methodology & Sources of Information
            1.5.1 Research Methodology
            1.5.2 Research Process
            1.5.3 Base Year
            1.5.4 Report Assumptions & Caveats
    2 Global Non-alcoholic Steatohepatitis Overall Market Size
        2.1 Global Non-alcoholic Steatohepatitis Market Size: 2023 VS 2030
        2.2 Global Non-alcoholic Steatohepatitis Market Size, Prospects & Forecasts: 2019-2030
        2.3 Key Market Trends, Opportunity, Drivers and Restraints
            2.3.1 Market Opportunities & Trends
            2.3.2 Market Drivers
            2.3.3 Market Restraints
    3 Company Landscape
        3.1 Top Non-alcoholic Steatohepatitis Players in Global Market
        3.2 Top Global Non-alcoholic Steatohepatitis Companies Ranked by Revenue
        3.3 Global Non-alcoholic Steatohepatitis Revenue by Companies
        3.4 Top 3 and Top 5 Non-alcoholic Steatohepatitis Companies in Global Market, by Revenue in 2023
        3.5 Global Companies Non-alcoholic Steatohepatitis Product Type
        3.6 Tier 1, Tier 2 and Tier 3 Non-alcoholic Steatohepatitis Players in Global Market
            3.6.1 List of Global Tier 1 Non-alcoholic Steatohepatitis Companies
            3.6.2 List of Global Tier 2 and Tier 3 Non-alcoholic Steatohepatitis Companies
    4 Market Sights by Product
        4.1 Overview
            4.1.1 By Type - Global Non-alcoholic Steatohepatitis Market Size Markets, 2023 & 2030
            4.1.2 Solid
            4.1.3 Liquid
        4.2 By Type - Global Non-alcoholic Steatohepatitis Revenue & Forecasts
            4.2.1 By Type - Global Non-alcoholic Steatohepatitis Revenue, 2019-2024
            4.2.2 By Type - Global Non-alcoholic Steatohepatitis Revenue, 2025-2030
            4.2.3 By Type - Global Non-alcoholic Steatohepatitis Revenue Market Share, 2019-2030
    5 Sights by Application
        5.1 Overview
            5.1.1 By Application - Global Non-alcoholic Steatohepatitis Market Size, 2023 & 2030
            5.1.2 Oral
            5.1.3 Parenteral
        5.2 By Application - Global Non-alcoholic Steatohepatitis Revenue & Forecasts
            5.2.1 By Application - Global Non-alcoholic Steatohepatitis Revenue, 2019-2024
            5.2.2 By Application - Global Non-alcoholic Steatohepatitis Revenue, 2025-2030
            5.2.3 By Application - Global Non-alcoholic Steatohepatitis Revenue Market Share, 2019-2030
    6 Sights by Region
        6.1 By Region - Global Non-alcoholic Steatohepatitis Market Size, 2023 & 2030
        6.2 By Region - Global Non-alcoholic Steatohepatitis Revenue & Forecasts
            6.2.1 By Region - Global Non-alcoholic Steatohepatitis Revenue, 2019-2024
            6.2.2 By Region - Global Non-alcoholic Steatohepatitis Revenue, 2025-2030
            6.2.3 By Region - Global Non-alcoholic Steatohepatitis Revenue Market Share, 2019-2030
        6.3 North America
            6.3.1 By Country - North America Non-alcoholic Steatohepatitis Revenue, 2019-2030
            6.3.2 US Non-alcoholic Steatohepatitis Market Size, 2019-2030
            6.3.3 Canada Non-alcoholic Steatohepatitis Market Size, 2019-2030
            6.3.4 Mexico Non-alcoholic Steatohepatitis Market Size, 2019-2030
        6.4 Europe
            6.4.1 By Country - Europe Non-alcoholic Steatohepatitis Revenue, 2019-2030
            6.4.2 Germany Non-alcoholic Steatohepatitis Market Size, 2019-2030
            6.4.3 France Non-alcoholic Steatohepatitis Market Size, 2019-2030
            6.4.4 U.K. Non-alcoholic Steatohepatitis Market Size, 2019-2030
            6.4.5 Italy Non-alcoholic Steatohepatitis Market Size, 2019-2030
            6.4.6 Russia Non-alcoholic Steatohepatitis Market Size, 2019-2030
            6.4.7 Nordic Countries Non-alcoholic Steatohepatitis Market Size, 2019-2030
            6.4.8 Benelux Non-alcoholic Steatohepatitis Market Size, 2019-2030
        6.5 Asia
            6.5.1 By Region - Asia Non-alcoholic Steatohepatitis Revenue, 2019-2030
            6.5.2 China Non-alcoholic Steatohepatitis Market Size, 2019-2030
            6.5.3 Japan Non-alcoholic Steatohepatitis Market Size, 2019-2030
            6.5.4 South Korea Non-alcoholic Steatohepatitis Market Size, 2019-2030
            6.5.5 Southeast Asia Non-alcoholic Steatohepatitis Market Size, 2019-2030
            6.5.6 India Non-alcoholic Steatohepatitis Market Size, 2019-2030
        6.6 South America
            6.6.1 By Country - South America Non-alcoholic Steatohepatitis Revenue, 2019-2030
            6.6.2 Brazil Non-alcoholic Steatohepatitis Market Size, 2019-2030
            6.6.3 Argentina Non-alcoholic Steatohepatitis Market Size, 2019-2030
        6.7 Middle East & Africa
            6.7.1 By Country - Middle East & Africa Non-alcoholic Steatohepatitis Revenue, 2019-2030
            6.7.2 Turkey Non-alcoholic Steatohepatitis Market Size, 2019-2030
            6.7.3 Israel Non-alcoholic Steatohepatitis Market Size, 2019-2030
            6.7.4 Saudi Arabia Non-alcoholic Steatohepatitis Market Size, 2019-2030
            6.7.5 UAE Non-alcoholic Steatohepatitis Market Size, 2019-2030
    7 Non-alcoholic Steatohepatitis Companies Profiles
        7.1 AstraZeneca
            7.1.1 AstraZeneca Company Summary
            7.1.2 AstraZeneca Business Overview
            7.1.3 AstraZeneca Non-alcoholic Steatohepatitis Major Product Offerings
            7.1.4 AstraZeneca Non-alcoholic Steatohepatitis Revenue in Global Market (2019-2024)
            7.1.5 AstraZeneca Key News & Latest Developments
        7.2 Pfizer
            7.2.1 Pfizer Company Summary
            7.2.2 Pfizer Business Overview
            7.2.3 Pfizer Non-alcoholic Steatohepatitis Major Product Offerings
            7.2.4 Pfizer Non-alcoholic Steatohepatitis Revenue in Global Market (2019-2024)
            7.2.5 Pfizer Key News & Latest Developments
        7.3 GSK
            7.3.1 GSK Company Summary
            7.3.2 GSK Business Overview
            7.3.3 GSK Non-alcoholic Steatohepatitis Major Product Offerings
            7.3.4 GSK Non-alcoholic Steatohepatitis Revenue in Global Market (2019-2024)
            7.3.5 GSK Key News & Latest Developments
        7.4 Novo Nordisk
            7.4.1 Novo Nordisk Company Summary
            7.4.2 Novo Nordisk Business Overview
            7.4.3 Novo Nordisk Non-alcoholic Steatohepatitis Major Product Offerings
            7.4.4 Novo Nordisk Non-alcoholic Steatohepatitis Revenue in Global Market (2019-2024)
            7.4.5 Novo Nordisk Key News & Latest Developments
        7.5 Roche
            7.5.1 Roche Company Summary
            7.5.2 Roche Business Overview
            7.5.3 Roche Non-alcoholic Steatohepatitis Major Product Offerings
            7.5.4 Roche Non-alcoholic Steatohepatitis Revenue in Global Market (2019-2024)
            7.5.5 Roche Key News & Latest Developments
        7.6 AbbVie
            7.6.1 AbbVie Company Summary
            7.6.2 AbbVie Business Overview
            7.6.3 AbbVie Non-alcoholic Steatohepatitis Major Product Offerings
            7.6.4 AbbVie Non-alcoholic Steatohepatitis Revenue in Global Market (2019-2024)
            7.6.5 AbbVie Key News & Latest Developments
        7.7 Galectin Therapeutics
            7.7.1 Galectin Therapeutics Company Summary
            7.7.2 Galectin Therapeutics Business Overview
            7.7.3 Galectin Therapeutics Non-alcoholic Steatohepatitis Major Product Offerings
            7.7.4 Galectin Therapeutics Non-alcoholic Steatohepatitis Revenue in Global Market (2019-2024)
            7.7.5 Galectin Therapeutics Key News & Latest Developments
        7.8 Galmed Pharmaceuticals
            7.8.1 Galmed Pharmaceuticals Company Summary
            7.8.2 Galmed Pharmaceuticals Business Overview
            7.8.3 Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Major Product Offerings
            7.8.4 Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Revenue in Global Market (2019-2024)
            7.8.5 Galmed Pharmaceuticals Key News & Latest Developments
        7.9 Gilead
            7.9.1 Gilead Company Summary
            7.9.2 Gilead Business Overview
            7.9.3 Gilead Non-alcoholic Steatohepatitis Major Product Offerings
            7.9.4 Gilead Non-alcoholic Steatohepatitis Revenue in Global Market (2019-2024)
            7.9.5 Gilead Key News & Latest Developments
        7.10 Intercept pharma
            7.10.1 Intercept pharma Company Summary
            7.10.2 Intercept pharma Business Overview
            7.10.3 Intercept pharma Non-alcoholic Steatohepatitis Major Product Offerings
            7.10.4 Intercept pharma Non-alcoholic Steatohepatitis Revenue in Global Market (2019-2024)
            7.10.5 Intercept pharma Key News & Latest Developments
        7.11 Non-alcoholic Steatohepatitis
            7.11.1 Non-alcoholic Steatohepatitis Company Summary
            7.11.2 Non-alcoholic Steatohepatitis Business Overview
            7.11.3 Non-alcoholic Steatohepatitis Non-alcoholic Steatohepatitis Major Product Offerings
            7.11.4 Non-alcoholic Steatohepatitis Non-alcoholic Steatohepatitis Revenue in Global Market (2019-2024)
            7.11.5 Non-alcoholic Steatohepatitis Key News & Latest Developments
        7.12 Takeda
            7.12.1 Takeda Company Summary
            7.12.2 Takeda Business Overview
            7.12.3 Takeda Non-alcoholic Steatohepatitis Major Product Offerings
            7.12.4 Takeda Non-alcoholic Steatohepatitis Revenue in Global Market (2019-2024)
            7.12.5 Takeda Key News & Latest Developments
    8 Conclusion
    9 Appendix
        9.1 Note
        9.2 Examples of Clients
        9.3 Disclaimer
    
  • Inquiry Before Buying

    Inquiry Before Buying

    Your personal details will remain secure and confidential - Privacy Policy

    WHY CHOOSE US

    Easy Access and Express Report Delivery Service
    Discover Business Growth Opportunities
    More than 10 Years Experience Employee Support
    In-depth and Comprehensive Analysis
    100+ Client Queries Handled Everyday
  • Request Sample

    Request For Sample

    Your personal details will remain secure and confidential - Privacy Policy

    WHY CHOOSE US

    Easy Access and Express Report Delivery Service
    Discover Business Growth Opportunities
    More than 10 Years Experience Employee Support
    In-depth and Comprehensive Analysis
    100+ Client Queries Handled Everyday


Our Trusted Clients
cooper.fr
koronos
waldenmedical
unioncomm.co.kr
technopathclinicaldiagnostics
toho-titanium.co.jp
straubmedical
sew-eurodrive.de
medurifarms
naperol
nvent
network.ae
petronas
saeedghodran
polyworldsys
seedplanning.co.jp
kraton
ipms.fraunhofer.de
infanttech
httpswww.castel-freres
hintoninfo
hexcel
freightways.co.nz
excelitas
Acco
aspet
brand
bmc
elevate
europ-assistance


GET IN TOUCH
Phone: +1 (415) 315-9432
Phone: +91 86698 89536
connect with us